Page last updated: 2024-10-22

alendronate and Nephrolithiasis

alendronate has been researched along with Nephrolithiasis in 3 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Nephrolithiasis: Formation of stones in the KIDNEY.

Research Excerpts

ExcerptRelevanceReference
"Idiopathic hypercalciuria is a metabolic abnormality with various causes and developmental pathways."2.55[Idiopathic hypercalciuria. Diagnosis and treatment]. ( Butnaru, DV; Gerasimenko, AS; Gorbatenko, VS; Olefir, YV; Shatalova, OV; Yavorskii, AN, 2017)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Olefir, YV1
Yavorskii, AN1
Butnaru, DV1
Shatalova, OV1
Gorbatenko, VS1
Gerasimenko, AS1
Assimos, DG1
Arrabal-Polo, MA1
Arias-Santiago, S1
de Haro-Muñoz, T1
Lopez-Ruiz, A1
Orgaz-Molina, J1
Gonzalez-Torres, S1
Zuluaga-Gomez, A1
Arrabal-Martin, M1

Reviews

1 review available for alendronate and Nephrolithiasis

ArticleYear
[Idiopathic hypercalciuria. Diagnosis and treatment].
    Urologiia (Moscow, Russia : 1999), 2017, Issue:6

    Topics: Alendronate; Female; Humans; Hypercalciuria; Male; Mutation; Nephrolithiasis; Receptors, Calcitriol

2017

Other Studies

2 other studies available for alendronate and Nephrolithiasis

ArticleYear
Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
    The Journal of urology, 2013, Volume: 190, Issue:2

    Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Humans; Hypercalciu

2013
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
    Urology, 2013, Volume: 81, Issue:4

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Fema

2013